SINOPHARM GROUP 1/5/O.N. (F:X2S1) — Stock Price
SINOPHARM GROUP 1/5/O.N. (F:X2S1) is currently trading at €8.25 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €8.05 and €11.80. This page tracks SINOPHARM GROUP 1/5/O.N.'s live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see X2S1 market cap.
SINOPHARM GROUP 1/5/O.N. (X2S1) Stock Price Chart — Daily History & Trading Volume
The chart below tracks SINOPHARM GROUP 1/5/O.N.'s daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
SINOPHARM GROUP 1/5/O.N. Income Statement — Revenue, Profit & Earnings by Year
SINOPHARM GROUP 1/5/O.N.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €575.17 Billion | €584.51 Billion | €596.57 Billion | €552.15 Billion | €521.05 Billion |
| Cost of Revenue | €533.50 Billion | €540.25 Billion | €548.06 Billion | €504.71 Billion | €477.00 Billion |
| Gross Profit | €41.67 Billion | €44.26 Billion | €48.51 Billion | €47.43 Billion | €44.05 Billion |
| Research & Development | — | — | — | — | — |
| SG&A | €24.02 Billion | €25.57 Billion | €26.15 Billion | €24.90 Billion | €23.20 Billion |
| Total Operating Expenses | €558.09 Billion | €566.74 Billion | €574.29 Billion | €529.61 Billion | €500.04 Billion |
| Operating Income | €17.08 Billion | €17.77 Billion | €22.28 Billion | €22.54 Billion | €21.01 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €2.30 Billion | €2.73 Billion | €2.96 Billion | €3.52 Billion | €3.76 Billion |
| Income Before Tax | €14.80 Billion | €14.00 Billion | €19.51 Billion | €18.56 Billion | €17.00 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €7.16 Billion | €7.05 Billion | €9.05 Billion | €8.53 Billion | €7.76 Billion |
SINOPHARM GROUP 1/5/O.N. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes SINOPHARM GROUP 1/5/O.N.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €390.36 Billion | €392.83 Billion | €383.39 Billion | €364.78 Billion | €335.41 Billion |
| Total Current Assets | €346.80 Billion | €347.45 Billion | €336.84 Billion | €319.41 Billion | €290.92 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €129.00K | €158.00K | €547.00K | €498.00K | €11.75 Million |
| Net Receivables | €194.61 Billion | €187.64 Billion | €169.00 Billion | €155.58 Billion | €161.40 Billion |
| Inventory | €63.34 Billion | €62.35 Billion | €60.03 Billion | €60.93 Billion | €51.50 Billion |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €5.78 Billion | €6.25 Billion | €7.19 Billion | €7.16 Billion | €7.20 Billion |
| Total Liabilities | €256.20 Billion | €266.14 Billion | €263.08 Billion | €254.71 Billion | €235.76 Billion |
| Total Current Liabilities | €246.73 Billion | €250.38 Billion | €241.49 Billion | €234.96 Billion | €219.31 Billion |
| Long-term Debt | €3.65 Billion | €8.64 Billion | €13.83 Billion | €11.75 Billion | €8.42 Billion |
| Net Debt | €18.17 Billion | €17.05 Billion | €4.76 Billion | €9.53 Billion | €20.04 Billion |
| Total Stockholder Equity | €83.95 Billion | €78.88 Billion | €74.58 Billion | €68.07 Billion | €61.89 Billion |
| Retained Earnings | €58.78 Billion | €53.74 Billion | €49.41 Billion | €42.91 Billion | — |
SINOPHARM GROUP 1/5/O.N. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how SINOPHARM GROUP 1/5/O.N. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €14.14 Billion | €11.55 Billion | €17.17 Billion | €20.96 Billion | €9.31 Billion |
| Capital Expenditures | €1.62 Billion | €1.97 Billion | €2.34 Billion | €2.42 Billion | €2.26 Billion |
| Free Cash Flow | €12.52 Billion | €9.58 Billion | €14.84 Billion | €18.55 Billion | €7.05 Billion |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €2.12 Billion | €2.71 Billion | €2.56 Billion | €2.34 Billion | €2.15 Billion |
| Stock-Based Compensation | — | — | — | — | €0.00 |
| Depreciation | €4.29 Billion | €4.73 Billion | €4.43 Billion | €4.17 Billion | €3.92 Billion |
| Change in Cash | €-5.51 Billion | €-9.49 Billion | €8.58 Billion | €11.68 Billion | €-6.65 Billion |
SINOPHARM GROUP 1/5/O.N. Earnings History — EPS Actual vs. Analyst Estimates
Track SINOPHARM GROUP 1/5/O.N.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 23, 2026 | — | — | — |
| Oct 23, 2025 | — | — | — |
| Apr 25, 2025 | — | — | — |
| Mar 20, 2025 | — | — | — |